JSB Market Research: PharmaPoint: Dry Eye Syndrome

  • View
    5

  • Download
    0

Embed Size (px)

DESCRIPTION

The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.

Transcript

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

    On 8th July 2014

    The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis.

    Browse Full Report @ http://www.jsbmarketresearch.com/healthcare-medical/r-PharmaPoint-Dry-Eye-Syndrome-Global-Drug-Forecast-and-Market-Analysis-118885

    Scope

    Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China, and India Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022 Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes Analysis of key recent licensing and partnership agreements in the DES Therapeutics market Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications Key topics covered include strategic competitor assessment, market characterization, unmet

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    needs and implications.

    Market Model Features

    An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model. *Model only available with site and global license purchases.

    Key Findings

    The global DES therapeutics market is forecast to reach $5.47 billion by 2022 due to the launch of novel pipeline drugs and an aging population. The global push for increased physician and patient awareness will increase diagnosis and treatment. By 2022, the DES market will be significantly more competitive, but the current dearth of treatment options leave much room for the coming pipeline therapies.

    Other industries we cover:

    Advertising and Media

    Automotive and Parts

    Consumer Goods

    Healthcare and Medical

    Finance and Banking

    Food and Beverages

    Travel and Tourism

    Textiles and Clothing

    SWOT Analysis

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    Table of Content

    2 Summary 8 2.1 Significant growth is expected in the DES market from 2012-2022. 8 2.2 Established players lack strong pipelines and will focus on filling this gap through acquisitions 10 2.3 With only one drug on the market in the US and two in Japan, there is a significant void to fulfill with pipeline products 10 2.4 The real opportunity for new players to market their new products and expand the patient base relies on improved diagnosis. 11 2.5 Pipeline agents offer patients expansion into new markets, novel mechanisms of action and longer-acting delivery systems. 11 2.6 What do the physicians think? 12 3 Introduction 14 3.1 Catalyst 14 3.2 Related Reports 14 4 Disease Overview 15 4.1 Etiology and Pathophysiology 15 4.1.1 Etiology 15 4.1.2 Pathophysiology 16 4.1.3 Classification 19 4.1.4 Prognosis 19 4.1.5 Quality of Life 20

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    4.2 Symptoms 20 5 Epidemiology 21 5.1 Risk Factors and Comorbidities 21 5.1.1 Risk of dry eye syndrome increases 35% each decade after age 40 22 5.1.2 Women are twice as likely to have dry eye syndrome as men 22 5.1.3 Use of certain medications may increase the risk of developing dry eye syndrome 23 5.1.4 Diets rich in omega-3 fatty acids help prevent dry eye syndrome 24 5.1.5 Certain environmental conditions can double the risk of dry eye syndrome 24 5.2 Global Trends 24 5.2.1 US 24 5.2.2 5EU 25 5.2.3 Asia 25 5.3 Forecast Methodology 26 5.3.1 Sources Used 26 5.3.2 Forecast Assumptions and Methods 27 5.3.3 Sources Not Used 29 5.4 Epidemiology Forecast (20122022) 30 5.4.1 Prevalent Cases of Dry Eye Syndrome 30 5.4.2 Age-Specific Prevalent Cases 31

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    5.4.3 Sex-Specific Prevalent Cases 34 5.4.4 Age-Standardized Prevalence of Dry Eye Syndrome 35 5.5 Discussion 36 5.5.1 Conclusions on Epidemiology Trends 36 5.5.2 Limitations of the Analysis 39 5.5.3 Strengths of the Analysis 39 6 Disease Management 39 6.1 Overview 39 6.1.1 Diagnosis Overview 39 6.1.2 Treatment Guidelines 43 6.1.3 Treatment Overview 47 6.2 US 50 6.2.1 Diagnosis 50 6.2.2 Clinical Practice 51 6.3 France 52 6.3.1 Diagnosis 52 6.3.2 Clinical Practice 53 6.4 Germany 54 6.4.1 Diagnosis 54 6.4.2 Clinical Practice 54

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    6.5 Italy 54 6.5.1 Diagnosis 54 6.5.2 Clinical Practice 54 6.6 Spain 56 6.6.1 Diagnosis 56 6.6.2 Clinical Practice 56 6.7 UK 57 6.7.1 Diagnosis 57 6.7.2 Clinical Practice 57 6.8 Japan 57 6.8.1 Diagnosis 57 6.8.2 Clinical Practice 58 6.9 China 60 6.9.1 Diagnosis 60 6.9.2 Clinical Practice 60 6.10 India 61 6.10.1 Diagnosis 61 6.10.2 Clinical Practice 61 7 Competitive Assessment 62

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    7.1 Overview 62 7.2 Strategic Competitor Assessment 62 7.3 Product Profiles Major Brands 63 7.3.1 Restasis (cyclosporine 0.05% ophthalmic emulsion) 63 7.3.2 Diquas (diquafosol tetrasodium) 69 7.3.3 Mucosta (rebamipide 2% ophthalmic suspension) 72 7.3.4 Additional Therapies 75 8 Opportunity and Unmet Need 78 8.1 Overview 78 8.2 Diagnostic tests are not specific enough to identify subgroups of patients 80 8.3 Frequent dosing and side effects limit compliance 81 8.4 Lack of physician and patient awareness 82 8.5 Trial design may be a factor in so few drugs being approved 83 8.6 Unmet Needs Gap Analysis 84 8.7 Comprehensive method for measuring dry eye signs and severity levels 85 8.8 Increase treatment rates among milder forms of the disease 86 9 Pipeline Assessment 86 9.1 Overview 86 9.2 Clinical Trial Mapping 87 9.2.1 Clinical Trials by Country 87

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    9.2.2 Clinical Trials by Phase and Trial Status 88 9.3 Promising drugs in clinical development 88 9.3.1 Lifitegrast 90 9.3.2 CF-101 94 9.3.3 Cyclokat 97 9.3.4 EGP-437 101 9.3.5 RX-10045 105 9.3.6 MIM-D3 109 10 Current and Future Players 112 10.1 Overview 112 10.2 Trends in Corporate Strategy 114 10.3 Company Profiles 115 10.3.1 Allergan 115 10.3.2 Alcon (a wholly-owned subsidiary of Novartis AG) 117 10.3.3 Santen Pharmaceutical 118 10.3.4 Shire/SARcode Bioscience 123 10.3.5 Otsuka Holdings 124 10.3.6 Can-Fite Biopharma 126 10.3.7 Eyegate Pharma 128

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    11 Market Outlook 129 11.1 Global Markets 129 11.1.1 Forecast 129 11.1.2 Drivers and Barriers Global Issues 131 11.2 United States 133 11.2.1 Forecast 133 11.2.2 Key Events 136 11.2.3 Drivers and Barriers 137 11.3 France 140 11.3.1 Forecast 140 11.3.2 Key Events 141 11.3.3 Drivers and Barriers 141 11.4 Germany 144 11.4.1 Forecast 144 11.4.2 Key Events 146 11.4.3 Drivers and Barriers 146 11.5 Italy 148 11.5.1 Forecast 148 11.5.2 Key Events 150 11.5.3 Drivers and Barriers 150

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    11.6 Spain 152 11.6.1 Forecast 152 11.6.2 Key Events 154 11.6.3 Drivers and Barriers 154 11.7 United Kingdom 154 11.7.1 Forecast 154 11.7.2 Key Events 157 11.7.3 Drivers and Barriers 157 11.8 Japan 159 11.8.1 Forecast 159 11.8.2 Key Events 161 11.8.3 Drivers and Barriers 161 11.9 China 163 11.9.1 Forecast 163 11.9.2 Key Events 165 11.9.3 Drivers and Barriers 165 11.10 India 167 11.10.1 Forecast 167 11.10.2 Key Events 168

  • Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/

    11.10.3 Drivers and Barriers 168 12 Appendix 169 12.1 Bibliography 169 12.2 Abbreviations 177 12.3 Methodology 178 12.4 Forecasting Methodology 178 12.4.1 Diagnosed DES patients 178 12.4.2 Percent Drug-treated Patients 180 12.4.3 Drugs Included in Each Therapeutic Class 180 12.4.4 Launch and Patent Expiry Dates 180 12.4.5 General Pricing Assumptions 180 12.4.6 Individual Drug Assumptions 182 12.4.7 Generic Erosi